Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  
Journal of Analytical Research in Clinical Medicine
   eISSN: 2345-4970  
Services
Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks
Mendeley

Cite by
Google Scholar



Article History
Submitted: 23 Jan 2018
Accepted: 03 Mar 2018
First published online: 05 Apr 2018

Article Access Statistics
Abstract Page Views: 74
PDF Downloads: 138
Full Text Views: 0

J Anal Res Clin Med. 2018;6(3):121-128 doi: 10.15171/jarcm.2018.019

Association of systemic lupus erythematosus activity with serum levelsof sTWEAK and CD160: A cross-sectional study

Original Article

Mehrzad Hajialilo 1, Amir Ghorbani Haghjo 2, Haleh Darbandi 3, Sepideh Karkon Shayan 4, Farid Karkon Shayan 5 *

1 Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Department of Biochemistry, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
3 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
4 Student Research Committee, Gonabad University of Medical Science, Gonabad, Iran
5 Medical Philosophy and History Research Center, Tabriz University of Medical Sciences, Tabriz, Iran



Abstract
Introduction: Systemic lupus erythematosus (SLE) is a relatively common disease among the patients referred to the rheumatology clinics. Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), as a cytokine, is a member of TNF family, and CD160 is an essential natural killer (NK) cell activator, both of which have been argued to be associated with SLE activity. Here, we aimed to evaluate the serum levels of sTWEAK and CD160 and their association with SLE activity. Methods: In a descriptive cross-sectional study, 48 patients with SLE, as the case group, and 40 healthy subjects, as controls, were enrolled. SLE activity was assessed using SLE Disease Activity Index (SLEDAI) in the case group. Moreover, the serum levels of sTWEAK and CD160 were determined using enzyme linked immunosorbent assays (ELISA) method in both groups. Results: Mean serum level of sTWEAK was 19.09% lower in the control group compared to the case group (730.15 ± 170.21 pg/ml vs. 895.39 ± 451.25 pg/ml, respectively). Further, mean serum level of CD160 was 47.31% lower in the healthy subjects than that of SLE patients (206.16 ± 88.97 pg/ml vs 391.30 ± 283.46 pg/ml, respectively). The differences in both occasions were found to be significant (P = 0.013 and P =0.001, respectively). Mean SLEDAI in the patients was 8.68 ± 4.00. There was no significant correlation between serum levels of sTWEAK and CD160 with SLE activity. Conclusion: The serum levels of sTWEAK and CD160 markers in patients with SLE are significantly higher than those of healthy subjects. However, we found no correlation of these markers with the disease activity.





Comments
First name  
Last name  
Email address  
Comments  
Security code



This Article
PDF

Google Scholar
Articles by Hajialilo M
Articles by Ghorbani Haghjo A
Articles by Darbandi H
Articles by Karkon Shayan S
Articles by Karkon Shayan F

PubMed
Articles by Hajialilo M
Articles by Ghorbani Haghjo A
Articles by Darbandi H
Articles by Karkon Shayan S
Articles by Karkon Shayan F



Share this article!
© 2017 Tabriz University of Medical Sciences; unless otherwise stated.

Press Manuscript Online. Powered by MAADRAYAN